Does Clarithromycin Cause QT Prolongation?
Yes, clarithromycin definitively causes QT interval prolongation and is associated with life-threatening ventricular arrhythmias including torsades de pointes, with documented fatalities. 1
FDA-Confirmed Risk
The FDA drug label explicitly warns that clarithromycin has been associated with QT prolongation and infrequent cases of arrhythmia, with spontaneous postmarketing reports of torsades de pointes and fatalities 1. This is not theoretical—it's a documented, real-world adverse effect that has killed patients.
Clinical Evidence
Among macrolide antibiotics, clarithromycin carries intermediate risk—lower than erythromycin but higher than azithromycin 2. In a multicenter study of everyday clinical practice, clarithromycin was one of the drugs that remained significantly associated with QTc prolongation after multivariate analysis 3.
Who Is at Highest Risk?
The FDA mandates avoiding clarithromycin in patients with 1:
- Known QT prolongation or ventricular arrhythmias (including torsades de pointes)
- Concurrent use of other QT-prolonging drugs
- Uncorrected hypokalemia or hypomagnesemia
- Clinically significant bradycardia
- Class IA (quinidine, procainamide, disopyramide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic use
Major risk factors from case reports 4, 5:
- Female sex (15 of 20 adult cases)
- Advanced age (elderly patients)
- Underlying heart disease (present in 17 of 20 cases)
- Electrolyte abnormalities, particularly hypokalemia 6, 5
Critically, 14 of 20 adults in case series had at least two major risk factors, and all had at least two risk factors beyond clarithromycin itself 4.
Critical Drug Interactions
Clarithromycin is contraindicated with 1:
- Cisapride and pimozide (cardiac arrhythmias, fatalities reported)
- Colchicine in patients with renal or hepatic impairment
The combination of clarithromycin with other QT-prolonging drugs substantially increases risk. When a patient is already on a QT-prolonging medication, choose an alternative antibiotic (penicillin or cephalosporin) rather than adding clarithromycin 2.
Practical Management Algorithm
Before prescribing clarithromycin:
Screen for absolute contraindications (baseline QTc ≥500 ms, known torsades de pointes, concurrent cisapride/pimozide use)
Assess risk factors:
- Female + elderly + heart disease = high risk
- Current QT-prolonging drugs
- Electrolyte disturbances
- Renal impairment (affects drug clearance)
If 2+ major risk factors present: Choose alternative antibiotic (penicillin, cephalosporin) 2
If proceeding with clarithromycin in moderate-risk patients:
High-risk threshold: QTc >500 ms or increase >60-70 ms indicates substantially increased torsades de pointes risk 2
Special Populations
Elderly patients are more susceptible to drug-associated QT effects 1. Children also demonstrate QTc prolongation with clarithromycin (average 22 ms increase), though clinical significance in pediatrics requires serial monitoring 7.
Common Pitfall
The most dangerous error is adding clarithromycin to patients already on QT-prolonging medications without considering safer alternatives. Hypokalemia dramatically potentiates clarithromycin's QT effects—even doses that wouldn't prolong QT alone can cause significant prolongation when combined with hypokalemia 6. Always check and correct electrolytes before initiating therapy.
Bottom Line for Practice
Clarithromycin is a proven QT-prolonging drug with documented fatal outcomes. In patients with multiple risk factors (female, elderly, heart disease, electrolyte abnormalities, concurrent QT-prolonging drugs), select a different antibiotic class entirely rather than attempting to monitor through the risk 2, 1.